Targeting GRK2 activity became an attractive antifibrotic strategy following the discovery that its inhibition, pharmacologically with paroxetine (45), or via viral delivery of a peptide inhibitor (βARKct) (46), conferred significant protection against cardiac dysfunction and myocardial fibrosis in numerous animal models of HF. This evidence concerns the gene GRK2 and hydrops fetalis.